Benitec Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-48.88	-37.92	-21.75	-19.56	-18.21	-13.88
Depreciation & Amortization	0.48	0.4	0.34	0.38	0.39	0.42
Stock-Based Compensation	33.6	17.43	0.83	0.45	0.87	0.63
Other Adjustments	-	-0.76	0	0	0.01	-0.02
Change in Receivables	0	0.2	-0.18	-0.05	0	0.03
Changes in Accounts Payable	-4.01	-2.38	0.94	1.36	1.09	0.06
Changes in Accrued Expenses	0.12	-0.08	0.04	0.07	0.08	0.12
Changes in Other Operating Activities	-1.09	-0.47	0.37	-0.67	-0.13	-0.2
Operating Cash Flow	-19.79	-23.59	-19.4	-18.01	-15.9	-12.83
Capital Expenditures	-0.03	-0.02	-0.18	-0	-0.01	-0.22
Investing Cash Flow	-0.03	-0.02	-0.18	-0	-0.01	-0.22
Issuance of Common Stock	160.07	72.8	73.92	17.88	-	25.75
Net Common Stock Issued (Repurchased)	160.07	72.8	73.92	17.88	-	25.75
Other Financing Activities	-3.13	-2.32	-5.89	-1.87	-	-3.23
Financing Cash Flow	101.48	70.49	68.03	16.02	-	22.52
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.23	0.05	-0.01	0.41	0.2	0.5
Net Cash Flow	81.43	46.93	48.44	-1.59	-15.71	9.97
Free Cash Flow	-19.82	-23.61	-19.58	-18.01	-15.91	-13.05
FCF Margin	-	-	-	-24017.30%	-21797.30%	-22123.70%
Free Cash Flow Per Share	-0.45	-0.65	-1.07	-13.00	-33.10	-51.66
Levered Free Cash Flow	-53.42	-40.47	-20.86	-18.42	-16.79	-13.7
Unlevered Free Cash Flow	-58.48	-44.31	-20.98	-17.94	-16.44	-13.41

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q